Literature DB >> 21706378

Semiparametric estimation of treatment effect with time-lagged response in the presence of informative censoring.

Xiaomin Lu1, Anastasios A Tsiatis.   

Abstract

In many randomized clinical trials, the primary response variable, for example, the survival time, is not observed directly after the patients enroll in the study but rather observed after some period of time (lag time). It is often the case that such a response variable is missing for some patients due to censoring that occurs when the study ends before the patient's response is observed or when the patients drop out of the study. It is often assumed that censoring occurs at random which is referred to as noninformative censoring; however, in many cases such an assumption may not be reasonable. If the missing data are not analyzed properly, the estimator or test for the treatment effect may be biased. In this paper, we use semiparametric theory to derive a class of consistent and asymptotically normal estimators for the treatment effect parameter which are applicable when the response variable is right censored. The baseline auxiliary covariates and post-treatment auxiliary covariates, which may be time-dependent, are also considered in our semiparametric model. These auxiliary covariates are used to derive estimators that both account for informative censoring and are more efficient then the estimators which do not consider the auxiliary covariates. © Springer Science+Business Media, LLC 2011

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21706378      PMCID: PMC3217309          DOI: 10.1007/s10985-011-9199-8

Source DB:  PubMed          Journal:  Lifetime Data Anal        ISSN: 1380-7870            Impact factor:   1.588


  9 in total

1.  Utilizing propensity scores to estimate causal treatment effects with censored time-lagged data.

Authors:  K J Anstrom; A A Tsiatis
Journal:  Biometrics       Date:  2001-12       Impact factor: 2.571

2.  Locally efficient estimation of the quality-adjusted lifetime distribution with right-censored data and covariates.

Authors:  M J van der Laan; A Hubbard
Journal:  Biometrics       Date:  1999-06       Impact factor: 2.571

3.  Efficient estimation of the distribution of quality-adjusted survival time.

Authors:  H Zhao; A A Tsiatis
Journal:  Biometrics       Date:  1999-12       Impact factor: 2.571

4.  Semiparametric Estimation of Treatment Effect in a Pretest-Posttest Study with Missing Data.

Authors:  Marie Davidian; Anastasios A Tsiatis; Selene Leon
Journal:  Stat Sci       Date:  2005-08       Impact factor: 2.901

5.  Covariance analysis of censored survival data.

Authors:  N Breslow
Journal:  Biometrics       Date:  1974-03       Impact factor: 2.571

6.  Evaluation of survival data and two new rank order statistics arising in its consideration.

Authors:  N Mantel
Journal:  Cancer Chemother Rep       Date:  1966-03

7.  A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.

Authors:  S M Hammer; D A Katzenstein; M D Hughes; H Gundacker; R T Schooley; R H Haubrich; W K Henry; M M Lederman; J P Phair; M Niu; M S Hirsch; T C Merigan
Journal:  N Engl J Med       Date:  1996-10-10       Impact factor: 91.245

8.  Covariate adjustment for two-sample treatment comparisons in randomized clinical trials: a principled yet flexible approach.

Authors:  Anastasios A Tsiatis; Marie Davidian; Min Zhang; Xiaomin Lu
Journal:  Stat Med       Date:  2008-10-15       Impact factor: 2.373

9.  Improving efficiency of inferences in randomized clinical trials using auxiliary covariates.

Authors:  Min Zhang; Anastasios A Tsiatis; Marie Davidian
Journal:  Biometrics       Date:  2008-01-11       Impact factor: 1.701

  9 in total
  5 in total

1.  Improved precision in the analysis of randomized trials with survival outcomes, without assuming proportional hazards.

Authors:  Iván Díaz; Elizabeth Colantuoni; Daniel F Hanley; Michael Rosenblum
Journal:  Lifetime Data Anal       Date:  2018-02-28       Impact factor: 1.588

2.  Improving Precision and Power in Randomized Trials for COVID-19 Treatments Using Covariate Adjustment, for Binary, Ordinal, and Time-to-Event Outcomes.

Authors:  David Benkeser; Iván Díaz; Alex Luedtke; Jodi Segal; Daniel Scharfstein; Michael Rosenblum
Journal:  medRxiv       Date:  2020-06-11

3.  Improving precision and power in randomized trials for COVID-19 treatments using covariate adjustment, for binary, ordinal, and time-to-event outcomes.

Authors:  David Benkeser; Iván Díaz; Alex Luedtke; Jodi Segal; Daniel Scharfstein; Michael Rosenblum
Journal:  Biometrics       Date:  2020-10-11       Impact factor: 1.701

4.  Optimising precision and power by machine learning in randomised trials with ordinal and time-to-event outcomes with an application to COVID-19.

Authors:  Nicholas Williams; Michael Rosenblum; Iván Díaz
Journal:  J R Stat Soc Ser A Stat Soc       Date:  2022-09-23       Impact factor: 2.175

5.  Sensitivity of adaptive enrichment trial designs to accrual rates, time to outcome measurement, and prognostic variables.

Authors:  Tianchen Qian; Elizabeth Colantuoni; Aaron Fisher; Michael Rosenblum
Journal:  Contemp Clin Trials Commun       Date:  2017-08-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.